S patentseach having one or more foreign counterparts

Prochymal is currently being evaluated in Phase III trialsfor steroid refractory GvHD, acute GvHD, and Crohns disease. Prochymal has beengranted Fast Track status by FDA for all three of these indications. Prochymalalso obtained Orphan Drug status by FDA and the European Medicines Agency forGvHD. Additionally, the Departmentof Defense recently awarded Osiris a contract to develop Prochymal as atreatment for acute radiation syndrome About Osiris TherapeuticsOsiris Therapeutics, Inc.

is the leading stem cell therapeutic company focusedon developing products to treat serious medical conditions in the inflammatory,orthopedic and cardiovascular areas. The Companys pipeline of internallydeveloped biologic drug candidates under evaluation includes Prochymal forinflammatory, autoimmune, and cardiovascular indications, as well as Chondrogenfor arthritis in the knee. for the developmentand commercialization of Prochymal and Chondrogen in countries outside theUnited States and Canada. Osiris has developed an extensive intellectualproperty portfolio to protect the company's technology including 47 U.S patentseach having one or more foreign counterparts. More information can befound on the company's website, (OSIR-G) Forward-Looking StatementsThis press release contains forward-looking statements. Forward-lookingstatements include statements about our expectations, beliefs, plans,objectives, intentions, assumptions and other statements that are not historicalfacts. Examples offorward-looking statements include, but are not limited to, statements regardingthe following: our product development efforts; our clinical trials andanticipated regulatory requirements and the ability to successfully navigatethese requirements; the success of our product candidates in development; statusof the regulatory process for our biologic drug candidates; implementation ofour corporate strategy; our financial performance; our product research anddevelopment activities and projected expenditures, including our anticipatedtimeline and clinical strategy for Prochymal, Chondrogen and our other MSC andbiologic drug candidates; our cash needs; patents and proprietary rights; thesafety and ability of our potential products to treat disease and the results ofour scientific research; our plans for sales and marketing; our plans regardingour facilities; types of regulatory frameworks we expect will be applicable toour potential products; and results of our scientific research.

Risks and uncertainties related to the Collaboration Agreement withGenzyme include, among others: typical business transactional risks; risksrelated to product development and clinical trial design, performance andcompletion; uncertainty of the success of Prochymal and Chondrogen in clinicaltrials and their ability to treat disease; Genzymes early termination andopt-out rights; the ability of Osiris and Genzyme to successfully navigateregulatory requirements and to manufacture and commercialize products; and theuncertainty as to the ability of the parties to successfully perform under thecollaborative arrangement and for Osiris to earn milestone and royalty paymentsthereunder. Our actual results could differ materially from those anticipated inforward-looking statements for many reasons, including the factors described inthe section entitled "Risk Factors" in our Annual Report on Form 10-K andQuarterly Reports filed on Form 10-Q, with the United States Securities andExchange Commission. Accordingly, you should not unduly rely on theseforward-looking statements. We undertake no obligation to publicly revise anyforward-looking statement to reflect circumstances or events after the date ofthis press release or to reflect the occurrence of unanticipated events. Osiris Therapeutics, Inc.Erica Elchin, orMedia:Schwartz CommunicationsStacey Holifield/Andrew Law, Copyright Business Wire 2009. Company Recognized for Market and Innovation Leadership and for Rapid RevenueGrowth of Its ON-Q Product LineLAKE FOREST, Calif.(Business Wire)I-Flow Corporation (NASDAQ:IFLO) won Frost & Sullivans 2009 North AmericanGrowth Strategy Leadership Award for its market leadership and revenue growth ofthe ON-Q Pain Relief System.